| Literature DB >> 28286759 |
Jiahong Xu1, Yang Liu1, Yuan Xie1, Cuimei Zhao1, Hongbao Wang2.
Abstract
Exercise-induced physiological cardiac hypertrophy is generally considered to be a type of adaptive change after exercise training and is beneficial for cardiovascular diseases. This study aims at investigating exercise-regulated microRNAs (miRNAs) and their potential biological pathways. Here, we collected 23 miRNAs from 8 published studies. MirPath v.3 from the DIANA tools website was used to execute the analysis, and TargetScan was used to predict the target genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses were performed to identify potential pathways and functional annotations associated with exercise-induced physiological cardiac hypertrophy. Various miRNA targets and molecular pathways, such as Fatty acid elongation, Arrhythmogenic right ventricular cardiomyopathy (ARVC), and ECM-receptor interaction, were identified. This study could prompt the understanding of the regulatory mechanisms underlying exercise-induced physiological cardiac hypertrophy.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28286759 PMCID: PMC5329648 DOI: 10.1155/2017/2850659
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The microRNAs regulated by exercise.
| MicroRNAs | Exercise training | Regulation | Reference |
|---|---|---|---|
| MiR-133a (rno-miR-133a-3p) | Running & swimming | Down | 17468766 & 21447748 |
| MiR-1 (rno-miR-1-3p) | Running & swimming | Down | 17468766 & 21447748 |
| MiR-27a (rno-miR-27a-3p) | Swimming | Up | 21709209 |
| MiR-27b (rno-miR-27b-3p) | Swimming | Up | 21709209 |
| MiR-143 (rno-miR-143-3p, mmu-miR-143-3p) | Swimming & wheel running | Down | 21709209 & 24751578 |
| miR-26b (mmu-miR-26b-5p) | Wheel running | Down | 24751578 |
| miR-150 (mmu-miR-150-5p) | Wheel running | Up | 24751578 |
| miRNA-133b (rno-miR-133b-3p) | Swimming | Down | 21447748 |
| miRNA-29c (rno-miR-29c-3p) | Swimming | Up | 21447748 |
| miRNA-214 (rno-miR-214-3p) | Jumping | Down | 25822872 |
| miR-208b (rno-mir-208b) | Swimming | Up | 25793527 |
| miR-30e (rno-miR-30e-5p) | Swimming | Up | 25793527 |
| miR-19b (rno-miR-19b-3p) | Swimming | Up | 25793527 |
| miR-99b (rno-miR-99b-5p) | Swimming | Down | 25793527 |
| miR-100 (rno-miR-100-5p) | Swimming | Down | 25793527 |
| miR-191a (rno-mir-191a) | Swimming | Down | 25793527 |
| miR-22 (rno-miR-22-3p) | Swimming | Down | 25793527 |
| miR-181a (rno-miR-181a-5p) | Swimming | Down | 25793527 |
| miR-222 (mmu-miR-222-3p) | Swimming & wheel running | Up | 25863248 |
| miRNA-21 (rno-miR-21-5p) | Swimming | Up | 23812090 |
| miRNA-145 (rno-miR-145-5p) | Swimming | Up | 23812090 |
| miRNA-144 (rno-miR-144-3p) | Swimming | Up | 23812090 |
| miRNA-124 (rno-miR-124-3p) | Swimming | Down | 23812090 |
The KEGG pathways incorporated by downregulated miRNAs.
| KEGG pathway | −log( | Genes |
|---|---|---|
| Fatty acid elongation | 4.84 | Hadha, Elovl6 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 2.94 | Cacng4, Cacna2d1, Sgcd, Jup, Itgb8, Gja1 |
| Other types of O-glycan biosynthesis | 2.34 | B3glct, Pomt2, Fut9, Colgalt2 |
| Thyroid hormone synthesis | 2.04 | Duox2, Tg |
| Tyrosine metabolism | 2.04 | Maoa, Aldh1a3 |
| Mucin type O-Glycan biosynthesis | 1.76 | Galnt16, Galnt7 |
| Other glycan degradation | 1.66 | Neu3 |
| Glycosphingolipid biosynthesis-lacto and neolacto series | 1.66 | B3galt2, Fut9 |
| Tryptophan metabolism | 1.66 | Afmid, Hadha, Tph2, Maoa, Ogdhl |
| Gap junction | 1.66 | Tjp1, Egfr, Nras, Grm5, Gja1 |
| Proteoglycans in cancer | 1.66 | Wnt2, Cttn, Wnt4, Fgfr1, Egfr, Fn1, Nras, Erbb3, Rock2, Flna, Fzd3, Wnt2b, Pik3cd, Cav3, Ppp1cc |
| Signaling pathways regulating pluripotency of stem cells | 1.57 | Fgfr3, Wnt2, Wnt4, Fgfr1, Nras, Nodal, Smad4, Fzd3, Wnt2b, Pik3cd, Acvr1c |
Figure 1The KEGG and GO pathways incorporated by downregulated microRNAs.
The KEGG pathways incorporated by upregulated miRNAs.
| KEGG pathway | −log( | Genes |
|---|---|---|
| ECM-receptor interaction | 55.86 | Col2a1, Col3a1, Col6a3, Col1a1, Col4a4, Col5a2, Col5a3, Col4a1, Col4a3, Col11a1, Col4a2, Col5a1 |
| Fatty acid degradation | 16.12 | Hadha, Ehhadh, Acadm |
| Fatty acid metabolism | 9.93 | Hadha, Ehhadh, Acadm |
| Amoebiasis | 6.21 | Col2a1, Col3a1, Col1a1, Prkx, Col4a4, Col5a2, Col5a3, Col4a1, Col4a3, Col11a1, Col4a2, Col5a1 |
| Fatty acid elongation | 4.85 | Hadha |
| Protein digestion and absorption | 3.93 | Col2a1, Col3a1, Col6a3, Col1a1, Col4a4, Col5a2, Col5a3, Col9a1, Col4a1, Col4a3, Col11a1, Atp1b4, Col4a2, Col5a1 |
| PI3K-Akt signaling pathway | 2.81 | Tsc1.Col2a1.Col3a1.Ddit4.Fgf.Col6a3.Lpar6.Fgf12.Eif4b.Col1a1.Irs1.Them4.Vegfa. Egfr.Ppp2ca.Ghr.Col4a.Tek.Col5a2.Osmr.Ppp2cb.Col5a.Ppp2r3c.Gng5.Col4a1. Col4a.Col11a1.Myb.Gnb3.Col4a.Col5a1.Kit |
| Tyrosine metabolism | 2.36 | Maoa, ldh1a3 |
| Other types of O-glycan biosynthesis | 2.23 | Pomt2, Fut9, Colgalt2 |
| Glycosphingolipid biosynthesis-lacto and neolacto series | 1.81 | B3galt2, Fut9 |
| Valine, leucine and isoleucine degradation | 1.81 | Hadha, Ehhadh, Acadm |
| Focal adhesion | 1.41 | Col2a1.Col3a1.Vav3.Col6a3.Col1a1.Vegfa.Crkl.Egfr.Col4a.Col5a2.Col5a3.Mylk. Col4a1.Col4a3.Col11a1.Col4a2.Col5a1.Ppp1ccsee interacti |
Figure 2The KEGG and GO pathways incorporated by upregulated microRNAs.